• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Glyphosate Vedotin for Treatment of Bone Metastatic Castration-Resistant Prostate Cancer.
【24h】

Glyphosate Vedotin for Treatment of Bone Metastatic Castration-Resistant Prostate Cancer.

机译：草甘膦Vedotin治疗骨转移性去势抵抗前列腺癌。

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

When prostate cancer is confined within the prostate, surgery or radiation therapy will cure almost all of them. When prostate cancer spreads to the lymph nodes or other organs, it is treated by androgen ablative therapy including drugs or surgery. However, the tumors eventually re-grow and become so called castration-resistant prostate cancer (CRPC) in about 2 years. Bone metastatic CRPC causes severe pain, pathologic fracture, spinal cord compression and paralysis, impairment of the quality of life, and eventual death. However, there is no effective treatment available for bone metastatic CRPC. In this project, we propose to create a new drug and test its selective anti-cancer effects in the cultured prostate cancer cell lines (Specific Aim 1) and in the bone tumor animal models that mimic human bone metastatic CRPC (Specific Aim 2). This drug is a conjugation of glyphosate (with a phosphate group that we predict will bind to calcium in the bone matrix, thus enriching the compound in the bone) and a toxin Vedotin (chemical name is monomethyl auristatin E, MMAE).

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号